# Iteration 006 Blind Review — Evidence Provenance + Study-Level Takeaways

Score: **88/100 PASS**

## Focus

Reviewed `/tmp/caseprep-live-right-parasagittal-4cm-meningioma-sss-v7/07-evidence.md` for the targeted change: replace confusing live-retrieval provenance/count framing with explicit curated-pack provenance, add concise study-level numeric takeaways, and preserve the parasagittal/SSS clinical constraints.

## Strengths

- Major improvement in provenance clarity: the rendered evidence distinguishes curated parasagittal/SSS pack coverage from narrow live retrieval counts.
- Quantitative takeaways are clinically useful and mostly accurate against checked PubMed/full-text summaries.
- Evidence framing preserves `abutting SSS` as invasion-unknown, requiring MRV/CTV and operative confirmation before assuming sinus wall invasion.
- Operative implication remains appropriate: venous preservation, safe stop points, planned residual/adjuvant radiation when sinus or dominant venous drainage is endangered.
- No irrelevant mandatory MEP/SSEP language introduced.
- No large Sindou-style matrix introduced.
- Machine-readable `provenance.json` now includes `case.evidence.curated_pack.parasagittal_sss` with 10 curated source IDs.

## Remaining caveats

- Curated pack selection would be stronger with a formal verification date/source-selection note if this becomes a formal evidence product.
- Radiosurgery-control numbers should be interpreted mainly for residual/smaller treated volumes or selected primary-radiosurgery cases, not automatic upfront treatment of an entire 4 cm lesion.
- Khanna recurrence data mix parafalcine/parasagittal tumors and grades; the current applicability caveat is acceptable, but this should not be used as patient-specific recurrence counseling before pathology and residual status are known.

## Verdict

Commit is appropriate for the targeted evidence/provenance slice.
